BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BGNE
- Previous Close: $38.57
- 50 Day Moving Average: $35.28
- 200 Day Moving Average: $31.92
- 52-Week Range: $32,933,000.00 - $24.53
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.47
- P/E Growth: 0.00
- Market Cap: $1.26B
- Outstanding Shares: 32,933,000
- Return on Equity: -79.29%
- Return on Assets: -50.13%
Companies Related to BeiGene:
- Debt-to-Equity Ratio: 0.10%
- Current Ratio: 7.16%
- Quick Ratio: 7.16%
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?
5 brokers have issued 1-year target prices for BeiGene's shares. Their forecasts range from $33.00 to $44.00. On average, they anticipate BeiGene's share price to reach $40.00 in the next twelve months.
When will BeiGene announce their earnings?
BeiGene is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.
What are analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/17/2017)
Maxim Group analysts commented, "Today, AbbVie presented a five-year analysis and follow-up data of its BTK inhibitor Imbruvica (ibrutinib) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at the American Society of Hematology’s (ASH) Annual Meeting and Exposition. Conclusion. While BeiGene’s Phase I study data is still early compared to Imbruvica’s five-year follow-up analysis in a larger patient population, BGB-3111 showed a high response rate in relapsed/refractory CLL/SLL at a lower dose than Imbruvica at median follow-up of 7.5 months. Data so far supports BGB-3111’s demonstration of high potency and greater selectivity vs. Imbruvica, which could potentially be the best-in-class BTK inhibitor, pending additional data from clinical development." (12/5/2016)
Cowen and Company analysts commented, "BeiGene reported positive Phase I data in Waldenstrom’s Macroglobulinemia (WM) for." (10/7/2016)
Who owns BeiGene stock?
BeiGene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.78%), Orbimed Advisors LLC (2.74%), Boxer Capital LLC (2.58%), Brown Advisory Inc. (1.39%), Temasek Holdings Private Ltd (1.15%) and Artal Group S.A. (0.91%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan and Thomas Malley.
Who bought BeiGene stock? Who is buying BeiGene stock?
BeiGene's stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, FMR LLC, Boxer Capital LLC, Artal Group S.A., Brown Advisory Inc., Guggenheim Capital LLC, State Street Corp and Baillie Gifford & Co.. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley.
How do I buy BeiGene stock?
Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BeiGene stock cost?
One share of BeiGene stock can currently be purchased for approximately $38.12.